Advertisement

Pharmaceutical Research

, Volume 19, Issue 11, pp 1753–1756 | Cite as

Complexation of VEGF with Bevacizumab Decreases VEGF Clearance in Rats

  • Vanessa Hsei
  • Geralyn G. DeGuzman
  • Allison Nixon
  • Jacques Gaudreault
Article
pharmacokinetics bevacizumab monoclonal antibody antigen-antibody clearance VEGF 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    J. Rak, B. St. Croix, and R. Kerbel. Consequences of angiogenesis for tumor progression, metastasis, and cancer therapy.Anticancer Drugs 6:3-18 (1995).Google Scholar
  2. 2.
    J. Folkman. What is the evidence that tumors are angiogenesis dependent? J.Natl.Cancer Inst. 82:4-6 (1990).PubMedGoogle Scholar
  3. 3.
    N. Ferrara and T. David-Smith. The biology of vascular endothelial growth factor. Endocr.Rev. 18:4-22 (1997).PubMedGoogle Scholar
  4. 4.
    S. Eppler, E. R. McCluskey, T. D. Henry, M. Simons, F. J. Giordano, and T. F. Zioncheck. Unique kinetics and hemodynamics of vascular endothelial growth factor (rhVEGF) following intracoronary and intravenous infusion in humans. J.Am.Col.Cardiol. 35:73A-74A (2000).Google Scholar
  5. 5.
    H. P. Gerber, J. Kowalski, D. Sherman, D. A. Eberhard, and N. Ferrara. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60:6253-6258 (2000).PubMedGoogle Scholar
  6. 6.
    L. G. Presta, H. Chen, S. J. O'Connor, V. Chisolm, Y. G. Meng, L. Krummen, M. Winkler, and N. Ferrara. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:4593-4599 (1997).PubMedGoogle Scholar
  7. 7.
    N. E. Simister, I. E. Jacobowitz, J. C. Ahouse, and C. M. Story. New functions of the MHC class I-related Fc receptor, FcRn. Biochem.Soc.Trans. 25:481-486 (1997).PubMedGoogle Scholar
  8. 8.
    Y. S. Lin, C. Nguyen, J. L. Medoza, E. Escandon, D. Fei, Y. G. Meng, and N. B. Modi. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J.Pharmacol.Exp.Ther. 288:371-378 (1999).PubMedGoogle Scholar
  9. 9.
    K. J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H. S. Phillips, and N. Ferrara. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844 (1993).PubMedGoogle Scholar
  10. 10.
    E. Bergsland, H. Hurwitz, L. Fehrenbacher, N. J. Meropol, W. F. Novotny, J. Gaudreault, G. Lieberman, and F. Kabbinavar. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. PASCO 19:242a (2000).Google Scholar
  11. 11.
    R. F. DeVore, L. Fehrenbacher, R. S. Herbet, C. J. Langer, K. Kelly, J. Gaudreault, E. Holmgren, W. F. Novotny, and F. Kabbinavar. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. PASCO 19:485a (2000).Google Scholar
  12. 12.
    M. S. Gordon, K. Margolin, M. Talpaz, G. W. Sledge Jr., E. Holmgren, R. Benjamin, S. Stalter, S. Shak, and D. C. Adelman. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J.Clin.Oncol. 19:843-850 (2001).PubMedGoogle Scholar
  13. 13.
    B. Q. Shen, D. Y. Lee, H. P. Gerber, B. A. Keyt, N. Ferrara, and T. F. Zioncheck. Homologous up-regulation of KDR/Flk-1 receptor expression by vacular endothelial growth factor in vitro. J.Biol.Chem. 273:29979-29985 (1998).PubMedGoogle Scholar
  14. 14.
    J. Liu, P. Lester, S. Builder, and S. J. Shire. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34:10474-10482 (1995).PubMedGoogle Scholar
  15. 15.
    J. A. Fox, T. E. Hotaling, C. Struble, J. Ruppel, D. J. Bates, and M. B. Schoenhoff. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in Cynomolgus monkeys. J.Pharmacol.Exp.Ther. 279:1000-1008 (1996).PubMedGoogle Scholar
  16. 16.
    M. Schoenhoff, D. Bate, J. Ruppel, D. Fei, J. A. Fox, D. Thomas, and P. Jardieu. Pharmacokinetics/dynamics following administration of a recombinant humanized monoclonal anti IgE antibody in cynomolgus monkeys. J.Allergy Clin.Immunol. 95:356 (1995).Google Scholar
  17. 17.
    H. Milgrom, R. B. Fick, J. Q. Su, J. D. Reimann, R. K. Bush, M. L. Watrous, and W. J. Metzger. Treatment of allergic asthma with monoclonal anti-IgE antibody. N.Engl.J.Med. 341:1966-1973 (1999).PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • Vanessa Hsei
    • 1
  • Geralyn G. DeGuzman
    • 2
  • Allison Nixon
    • 3
  • Jacques Gaudreault
    • 1
  1. 1.Clinical and Experimental PharmacologyGenentech, Inc.South San Francisco
  2. 2.Department of PhysiologyGenentech, Inc.South San Francisco
  3. 3.Vacaville Quality ControlGenentech, Inc.Vacaville

Personalised recommendations